^
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
orelabrutinib Sensitive: A1 - Approval
|
orelabrutinib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
duvelisib Sensitive: A1 - Approval
|
duvelisib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
PCR Sensitive: A2 - Guideline
|
PCR Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax Sensitive: A2 - Guideline
|
venetoclax Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
venetoclax Sensitive: A2 - Guideline
|
venetoclax Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
acalabrutinib Sensitive: A2 - Guideline
|
acalabrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
acalabrutinib Sensitive: A2 - Guideline
|
acalabrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
chlorambucil Sensitive: A2 - Guideline
|
chlorambucil Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
CD20 inhibitor Sensitive: A2 - Guideline
|
CD20 inhibitor Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
OFAR Sensitive: A2 - Guideline
|
OFAR Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
R-CVAD Sensitive: A2 - Guideline
|
R-CVAD Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
EPOCH-R Sensitive: A2 - Guideline
|
EPOCH-R Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
R-CHOP Sensitive: A2 - Guideline
|
R-CHOP Sensitive: A2 - Guideline
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
BR Sensitive: A2 - Guideline
|
BR Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
BR + ibrutinib Sensitive: A2 - Guideline
|
BR + ibrutinib Sensitive: A2 - Guideline
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
BR + idelalisib Sensitive: A2 - Guideline
|
BR + idelalisib Sensitive: A2 - Guideline
|
TP53 deletion
|
Small Lymphocytic Lymphoma
|
TP53 deletion
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
ibrutinib + obinutuzumab Sensitive: A2 - Guideline
|
ibrutinib + obinutuzumab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
rituximab + ibrutinib Sensitive: A2 - Guideline
|
rituximab + ibrutinib Sensitive: A2 - Guideline
|
BIRC3 mutation
|
Small Lymphocytic Lymphoma
|
BIRC3 mutation
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
ibrutinib + obinutuzumab Sensitive: B - Late Trials
|
ibrutinib + obinutuzumab Sensitive: B - Late Trials
|
IGH mutation
|
Small Lymphocytic Lymphoma
|
IGH mutation
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
Chr del(11q)
|
Small Lymphocytic Lymphoma
|
Chr del(11q)
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
Chr del(11q)
|
Small Lymphocytic Lymphoma
|
Chr del(11q)
|
Small Lymphocytic Lymphoma
|
zanubrutinib Sensitive: B - Late Trials
|
zanubrutinib Sensitive: B - Late Trials
|
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
|
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
|
LOXO-305 Sensitive: C3 – Early Trials
|
LOXO-305 Sensitive: C3 – Early Trials
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
LOXO-305 Sensitive: C3 – Early Trials
|
LOXO-305 Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
LOXO-305 Sensitive: C3 – Early Trials
|
LOXO-305 Sensitive: C3 – Early Trials
|
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
|
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
|
orelabrutinib Sensitive: C3 – Early Trials
|
orelabrutinib Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
orelabrutinib Sensitive: C3 – Early Trials
|
orelabrutinib Sensitive: C3 – Early Trials
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
orelabrutinib Sensitive: C3 – Early Trials
|
orelabrutinib Sensitive: C3 – Early Trials
|
Chr del(11q)
|
Small Lymphocytic Lymphoma
|
Chr del(11q)
|
Small Lymphocytic Lymphoma
|
orelabrutinib Sensitive: C3 – Early Trials
|
orelabrutinib Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab + zanubrutinib Sensitive: C3 – Early Trials
|
obinutuzumab + zanubrutinib Sensitive: C3 – Early Trials
|
IGH mutation
|
Small Lymphocytic Lymphoma
|
IGH mutation
|
Small Lymphocytic Lymphoma
|
FCR Sensitive: C3 – Early Trials
|
FCR Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
FCR Sensitive: C3 – Early Trials
|
FCR Sensitive: C3 – Early Trials
|
Chr del(17)(p13.1)
|
Small Lymphocytic Lymphoma
|
Chr del(17)(p13.1)
|
Small Lymphocytic Lymphoma
|
acalabrutinib Sensitive: C3 – Early Trials
|
acalabrutinib Sensitive: C3 – Early Trials
|
Chr del(11)(q22.3)
|
Small Lymphocytic Lymphoma
|
Chr del(11)(q22.3)
|
Small Lymphocytic Lymphoma
|
acalabrutinib Sensitive: C3 – Early Trials
|
acalabrutinib Sensitive: C3 – Early Trials
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
TP53 mutation
|
Small Lymphocytic Lymphoma
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
